Bruce Carleton, PharmD, FCP, FISPE (Vancouver, British Columbia) - Committee Chair
Bruce Carleton is Professor and Chair, Division of Clinical Pharmacology, Department of Pediatriics, University of British Columbia. He is a Senior Clinician Scientist at the BC Children’s Hospital Research Institute. He is also the CEO of the Canadian Pharmacogenomics Network for Drug Safety. He has a keen interest in advancing the safe and effective use of drugs, particularly in children. He is passionate about caring for kids.
Nasir Ali Afsar, MBBS, MPhil, PhD, AFAMEE (Pakistan)
Nasir Afsar is a Professor of Pharmacology at Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan. He is a member-designate of Canada Pakistan Research and Development Council (CPRDC). His research interests include pharmacogenetics, clinical pharmacology, clinical simulation and medical education. He has a keen interest in exploring pharmacogenomics in Pakistan and adjoining countries.
Marc Chretien, (London, Ontario)
Marc Chretien is a trained internist pursuing clinical research in the Clinical Investigator Program at the University of Western Ontario. Currently, Marc's research interests focus on chronic diseases of the gut and disease-related effects on drug absorption and metabolism in at-risk populations.
Anne Dittrich, MD, PhD student (The Netherlands)
Anne Dittrich is pediatrician in the Amalia Children’s Hospital Radboud UMC, in Nijmegen, the Netherlands. She works in the field of general pediatrics, and has a special interest in the supportive care of pediatric oncology patients. Besides her clinical work, Anne is a clinical pharmacologist in training and a PhD student. Her research focuses on adverse drug reactions in children. Her main goal is to improve drug safety for children.
Jorge Ganopolsky, PhD (Quebec)
Dr. Ganopolsky is Manager of Scientific Affairs at Dynacare Next. Dr. Ganopolsky works in the development and commercialization of specialized diagnostic tools for personalized medicine in order to provide actionable solutions for patients and healthcare providers. He has performed research in blood coagulation, inflammation, wound healing and in the role of the microbiome in metabolic disorders both in academia and industry settings.
Michelle Hildebrant (Houston, Texas)
David Lee (Ottawa, Ontario)
Colin Ross, PhD (Vancouver, British Columbia)
Colin Ross’ research aims to save and improve the lives of patients by developing new safer and more effective therapeutic options for patients based upon an individual’s genetic blueprint. Adverse drug reactions are a striking problem. In the treatment of childhood cancer, for example, 42% of patients develop permanently disabling or life-threatening adverse drug reactions.